FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents


Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Binds Eukaryotic Cell Or Component Thereof Or Substance Produced By Said Eukaryotic Cell (e.g., Honey, Etc.)

Binds Eukaryotic Cell Or Component Thereof Or Substance Produced By Said Eukaryotic Cell (e.g., Honey, Etc.)

Binds Eukaryotic Cell Or Component Thereof Or Substance Produced By Said Eukaryotic Cell (e.g., Honey, Etc.) patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

10/30/14 - 20140322235 - Anti-cd277 antibodies and uses thereof
The present invention relates to anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vy9/Vδ2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The invention also relates to...

10/30/14 - 20140322236 - Anti-human adora2a antibodies
The present invention provides novel antibodies to human ADORA2A....

10/30/14 - 20140322237 - Neurodegenerative diseases and methods of modeling
Disclosed are embryonic stem cells and motor neurons derived from mice carrying transgenic alleles of the normal or mutant human SOD1 gene. Also disclosed are in vitro systems employing such SOD1 transgenic motor neurons for the study of neural degenerative disease....

10/30/14 - 20140322238 - Il-17ra-il-17rb antagonists and uses thereof
The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor C form a heteromeric receptor complex that is biologically active. Antagonists of the IL-17RA-IL-17RB heteromeric receptor complex are disclosed, as well as various methods of use....

10/30/14 - 20140322239 - Anti-il-6 receptor antibodies and methods of use
The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases....

10/30/14 - 20140322240 - Malaria vaccine
The present invention provides an antigenically restricted subset of the highly variant PfEMP1 rosetting antigen which possess epitopes which may be exploited to raise immune responses effective against many diverse strains and isolates of the malaria parasite, Plasmodium falciparum. In this regard, the invention provides one or more P. falciparum...

10/30/14 - 20140322241 - Methods of regulating angiogenesis and compositions capable of same
A method of treating an angiogenesis related disease or disorder in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which regulates an amount of apolipoprotein B (ApoB), and/or an ability of ApoB to transcriptionally control vascular endothelial...

10/16/14 - 20140308295 - Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases
The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular...

10/16/14 - 20140308296 - Par-1 antagonists for use in the treatment or prevention of influenza virus type a infections
The present invention provides methods and compositions (such as pharmaceutical compositions) comprising PAR1 antagonists for treating or preventing influenza virus type A infections, in particular H1N1 infection. PAR1 antagonists may be combined with a PAR2 agonist....

10/16/14 - 20140308297 - Stem cell fusion model of carcinogenesis
Model systems and methods for exploring mechanisms of carcinogenesis and the acquisition of metastatic ability, and to provide insights into potential therapeutic targets. The systems include and methods involve fusion of a stem cell and a genetically altered cell to evaluate carcinogenesis and metastasis and for the discovery and evaluation...

10/16/14 - 20140308298 - Diagnostic and treatment of an androgen-independent prostate cancer
The present invention relates to a method for monitoring the tumor growth of an androgen-independent prostate cancer in a subject, by determining the amount of at least one adrenomedullin receptor and optionally adrenomedullin in a prostate cancer cell obtained from said subject. The present invention also relates to a pharmaceutical...

10/09/14 - 20140302064 - Optimized anti-cd3 variable regions
The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect,...

10/09/14 - 20140302065 - Soluble urokinase receptor (supar) in diabetic kidney disease
Methods and compositions are provided for diagnosing and treating a diabetic kidney disease (DKD) in an individual. In aspects of the methods, the levels of soluble circulating urokinase receptor (suPAR) in the blood are measured to predict a DKD, diagnose a DKD, or provide a prognosis pertaining to a DKD....

10/02/14 - 20140294859 - Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
The present invention relates to stable aqueous protein formulations. In particular, disclosed herein are therapeutic protein formulations suitable for parenteral administration having one or more antioxidants....

10/02/14 - 20140294860 - Means and methods for treating and/or preventing natural ahr ligand-dependent cancer
The present invention relates to the field of cancer therapeutics and treatment of cancer. In particular, it relates to a method for treating and/or preventing a natural AHR ligand-dependent cancer comprising administering to a subject suffering from said cancer a therapeutically effective amount of an AHR inhibitor. Moreover, contemplated is...

09/25/14 - 20140286966 - Methods and compositions for the treatment of metabolic syndrome, obstructive respiratory disorders, cancer and related diseases
Compositions comprising IGFBP-3 receptor agonists and methods for the treatment of metabolic syndrome, obstructive respiratory disorders, obstructive or inflammatory respiratory disease, cancers and related diseases with IGFBP-3 receptor agonists are presented. A method for interfering with the activity of nuclear factor-kappaB (NF-KB) in a cell, comprising: providing to a cell...

09/18/14 - 20140271671 - Random homozygous gene perturbation (rhgp) with thermal assymetric interlaced (tail)-pcr
A method for identifying host genes and encoded proteins for potential targets for therapeutic intervention employs a Gene Search Vector that is either lentivirus or MMLV-based, and can be used to interrogate an entire cell genome without prior knowledge of the genomic sequence. This Random Homozygous Gene Perturbation (RUGP) technique...

09/18/14 - 20140271672 - Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
The present invention is based on the discovery of genetic polymorphisms that are associated with myocardial infarction. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods...

09/18/14 - 20140271673 - Use of lxr antagonists for treatment of side effects of elevated glucocorticoid levels
The present application is directed to uses of an agent that antagonizes the LXRβ receptor for the treatment of side effects associated with elevated glucocorticoid levels as well as uses of a glucocorticoid in combination with the agent that antagonizes the LXRβ receptor for treatment of a disease wherein glucocorticoid...

09/18/14 - 20140271674 - Methods and materials for treating cancer
This document provides methods and materials involved in treating cancer. For example, methods and materials for identifying a mammal as having an elevated level of PD-1+/CD11ahigh CD8 T cells having the potential to exert anti-cancer effects are provided. In addition, methods and materials for identifying a mammal as having an...

09/18/14 - 20140271675 - Therapeutic uses for vegfr1 antibodies
The present invention relates to methods of using VEGFR1 antibodies for the treatment of chronic kidney disease....

09/18/14 - 20140271676 - Fc containing polypeptides with altered glycosylation and reduced effector function
Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine threonine residue at amino acid...

09/18/14 - 20140271677 - Newcastle disease viruses and uses thereof
Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such...

09/18/14 - 20140271678 - Diagnostic method for pediatric acute-onset neuropsychiatric syndrome (pans) and pediatric autoimmune neuropsychiatric disorder associated with streptococci infection (pandas)
The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (PANS) and/or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) in an individual. These include enzyme linked immunosorbent assays (ELISAs) to measure antibody...

09/18/14 - 20140271679 - Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-β, anti-RAGE, and anti-α-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions...

09/18/14 - 20140271680 - Methods and pharmaceutical compositions for treatment of pulmonary hypertension
The present invention relates to uses, methods and compositions for the treatment of pulmonary hypertension....

09/18/14 - 20140271681 - High affinity human antibodies to human il-4 receptor
The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (IL-4R). Also provided are expression vectors comprising nucleic acid molecule that encode anti-IL-4R antibodies, host cells comprising the expression vectors, and methods of producing anti-IL-4R antibodies or antigen-binding fragments thereof...

09/11/14 - 20140255427 - Combination therapy with an anti - cd19 antibody and a nitrogen mustard
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia....

09/11/14 - 20140255428 - Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
which possess inhibitory activity against activating mutant forms of EGFR, and are accordingly useful for their anti-cancer activity and in methods of treatment of the human or animal body. The invention also relates pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the...

09/11/14 - 20140255429 - Methods of treating autoimmune diseases with dll4 antagonists
The present invention provides methods of treating a disease or disorder, in which increasing the number of regulatory T cell (Treg) is beneficial, by administering to a subject suffering from such a disease or disorder a therapeutically effective amount of Dll4 antagonists that block Dll4-Notch signal pathways, thereby increasing the...

09/04/14 - 20140248287 - Fc receptor binding proteins
This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders....

09/04/14 - 20140248288 - Biodegradable metal alloys
The invention relates to biodegradable, metal alloy-containing compositions, methods for their preparation and applications for their use. The compositions include magnesium and other components, such as yttrium, calcium, silver, cerium, and zirconium; or zinc, silver, cerium, and zirconium; or aluminum, zinc, calcium, manganese, silver, yttrium; or strontium, calcium, zinc. The...

08/28/14 - 20140242093 - Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject
In one aspect, the present invention relates to methods for increasing, decreasing or maintaining the innate immune response in a mammalian subject comprising modulating the expression of DUX4-fl, or modulating the expression of beta-defensin 3 (DEFB103). In another aspect, the present invention relates to methods for increasing, decreasing or maintaining...

08/21/14 - 20140234340 - Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for...

08/21/14 - 20140234341 - Acute hepatic insufficiency depressant and method for evaluating drug efficacy thereof
The present invention provides a therapeutic agent for acute liver failure containing a hepatocyte growth factor (HGF), particularly an agent for treating fulminant hepatitis or late onset hepatic failure or suppression of progression of acute liver failure without hepatic coma to fulminant hepatitis or late onset hepatic failure. The present...

08/21/14 - 20140234342 - Nkp46-mediated nk cell tuning
The present invention relates to compounds (e.g. antibodies) that specifically bind and inhibit NKp46. Such compounds are capable, when administered to a mammal, capable of increasing the frequency of reactive and/or active NK cells. The invention also relates to pharmaceutical composition and methods of using the antibodies and compositions to...

08/21/14 - 20140234343 - Composition for prevention or treatment of ischemic cardiac disease, comprising inhibitor against age-albumin synthesis or release of mononuclear phagocyte system cells as active ingredient
Disclosed is a pharmaceutical composition for the prevention or treatment of ischemic heart diseases, comprising as an active ingredient an inhibitor which acts to restrain mononuclear phagocyte system cells from synthesizing or releasing AGE-albumin, which induces the apoptosis of cardiomyocytes upon the onset of the ischemic heart disease. Also, a...

08/14/14 - 20140227291 - Amyloid-beta binding proteins
The present invention relates to amyloid-beta (Aβ) binding proteins. Antibodies of the invention have high affinity to Aβ(20-42) globulomer or any Aβ form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided....

08/14/14 - 20140227292 - Anti-mcam antibodies and associated methods of use
Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin α-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration...

08/14/14 - 20140227293 - Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
The present invention provides methods and compositions for the treatment and prevention of angiogenesis, or cancer, e.g., metastatic cancer by administering an effective amount of an inhibitor of immunoglobulin containing proline rich receptor-1 (IGPR-1) protein or expression. In particular, the present invention provides methods and compositions for the treatment and...

08/14/14 - 20140227294 - Prolactin receptor binding proteins and uses thereof
The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding...

08/07/14 - 20140220036 - Methods for treating neurodegenerative diseases and for identifying agents useful for treating neurodegenerative diseases
The present invention provides methods of inhibiting a tau protein such as h-tau42 or a biologically active fragment, derivative or analog thereof, methods of treating a disease caused by a tau protein such as h-tau42, and methods to identify agents that may inhibit a tau protein such as h-tau42. The...

08/07/14 - 20140220037 - Methods for treating reperfusion injuries
The present invention relates to treating a tissue in a mammal from the effects of reperfusion using flagellin...

08/07/14 - 20140220038 - Lrp1 as key receptor for the transfer of sterified cholesterol from very-low-density lipoproteins (vldl) to ischaemic cardiac muscle
The invention relates to novel molecules that can modulate one of the mechanisms leading to the massive deposition of cholesterol in the cardiomyocytes and/or in the smooth muscle cells of the vascular wall, during acute myocardial infarction or other clinical situations involving ischaemia. The invention also shows that the blockage...

08/07/14 - 20140220039 - Apoiii and the treatment and diagnosis of diabetes
The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit...

08/07/14 - 20140220040 - Antibodies to lrp6
Anti-LRP6 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. These anti-LRP6 antibodies can be used to enhance Wnt activity and/or antagonize Dkk1 activity. Also described are methods of therapy using such antibodies and antigen-binding regions to bind modulate Wnt/LRP6 signaling...

08/07/14 - 20140220041 - Compounds for use in the treatment of alzheimer's disease
The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (β) and gamma (γ) secretases and amyloid beta peptide (Aβ), and also relates to a method of reducing Aβ shedding. Furthermore, this invention extends to a compound for use in...

07/31/14 - 20140212435 - Rapid clearance of antigen complexes using novel antibodies
The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma....

07/31/14 - 20140212436 - Rapid clearance of antigen complexes using novel antibodies
The present invention relates to rapid clearance molecules that bind target antigens and FcγRIIb with increased affinity as compared to parent molecules, said compositions being capable of causing accelerated clearance of such antigens. Such compositions are useful for treating a variety of disorders, including allergic diseases, atherosclerosis, and a variety...

07/31/14 - 20140212437 - Methods and compositions for treating atrial fibrillation
The present invention relates to compositions and methods for the prevention and treatment of atrial fibrillation. In particular, the present invention provides therapeutic agents for the treatment and prevention of persistent and permanent atrial fibrillation and prevention of progression of atrial fibrillation to permanent atrial fibrillation....

07/31/14 - 20140212438 - Nuclear targeting sequences
Isolated peptides comprising nuclear targeting activity or being capable of preventing endogenous nuclear targeting activity are disclosed. Polynucleotides encoding same, pharmaceutical compositions comprising same, as well as uses thereof are also disclosed....